Abstract
MM-1043: Efficacy of Elranatamab (ELRA) in Combination With Carfilzomib (CFZ) and Dexamethasone (DEX) in the Phase 1b MagnetisMM-20 Trial in Relapsed or Refractory Multiple Myeloma (RRMM)
Clinical lymphoma, myeloma and leukemia, Vol.25(Suppl 1), pp.S958-S959
09/2025
DOI: 10.1016/S2152-2650(25)02674-6
Abstract
ELRA induced deep and durable responses with manageable safety in BCMA-naïve patients with RRMM in MagnetisMM-3 (NCT04649359). Combining ELRA with CFZ may enhance immune surveillance of MM cells. Here we present the Part 1 results from the Phase 1b MagnetisMM-20 (NCT05675449) trial of ELRA+CFZ+DEX (EKd) in RRMM.
Eligible patients (≥18 years) had BCMA-naïve RRMM, 1–3 prior LOTs, and ECOG PS ≤1. Prior CFZ was allowed if ≥PR to most recent CFZcontaining therapy and no relapse ≤60 days after discontinuation, with a ≥6-month CFZ-free interval. Patients received premedication and 12- and 32-mg step-up priming doses on days 1 and 4 of cycle 0, followed by 44 mg (DL1) or 76 mg (DL2) on day 8. Patients with ≥6 months of QW dosing and ≥PR lasting ≥2 months switched to Q2W dosing. CFZ+DEX was administered per label. Primary endpoint is DLTs. Secondary endpoints include AEs, laboratory abnormalities, BOR, ORR, CRR, TTR, DOR, PFS, and OS.
Of the 12 treated patients, the median age was 66.0 years (range, 45.0–80.0), 8 (66.7%) were male, and 3 (25.0%) had high-risk cytogenics. Patients had a median of two prior LOTs (range, 1–3); 41.7% had triple-class refractory disease, and 8 (66.7%) had an SCT. At data cutoff (September 13, 2024), 41.7% had ongoing ELRA+CFZ treatment. Median treatment duration was 8.4 months (range, 0.6–20.1). No DLTs were reported (10 evaluable patients). The most common AEs overall (n = 12; any grade [≥50%], grade 3/4 [≥10%]) were infections (91.7%, 16.7%), fatigue (83.3%, 16.7%), CRS (75.0%, 0%), neutropenia (75.0%, 75.0%), thrombocytopenia (75.0%, 41.7%), leukopenia (66.7%, 33.3%), anemia (66.7%, 33.3%), cough (58.3%, 0%), diarrhea (50.0%, 8.3%), cytomegalovirus infection reactivation (50.0, 8.3%), injection site reaction (50.0%, 0%), lymphopenia (33.3%, 25.0%), peripheral edema (33.3%, 16.7%), increased blood alkaline phosphatase (25.0%, 16.7%), and pulmonary embolism (16.7%, 16.7%). No ICANS was reported. At a median follow-up (reverse Kaplan-Meier) of 8.9 months (95% CI, 7.9–13.7), confirmed ORR by investigator was 100%; median TTR was 1.5 months (range, 0.5–3.4). Median DOR was not reached.
EKd demonstrated clinical efficacy and predictable safety. The study continues enrolling and will explore this combination in a larger patient population.
Details
- Title: Subtitle
- MM-1043: Efficacy of Elranatamab (ELRA) in Combination With Carfilzomib (CFZ) and Dexamethasone (DEX) in the Phase 1b MagnetisMM-20 Trial in Relapsed or Refractory Multiple Myeloma (RRMM)
- Creators
- Michael Tomasson - University of IowaEli Gabayan - Beverley Hills Cancer Center, Beverly Hills, CA, USASyed Abbas Ali - The Sydney Kimmel Comprehensive Cancer Center, Baltimore, MD, USAGabriel Afram - PfizerSona Ghorashi - PfizerTrish Creel - PfizerLuisa Paccagnella - PfizerCarolyn Lou - PfizerOla Landgren - Sylvester Comprehensive Cancer Center
- Resource Type
- Abstract
- Publication Details
- Clinical lymphoma, myeloma and leukemia, Vol.25(Suppl 1), pp.S958-S959
- DOI
- 10.1016/S2152-2650(25)02674-6
- ISSN
- 2152-2650
- Publisher
- Elsevier Inc
- Language
- English
- Date published
- 09/2025
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Health, Sport, and Human Physiology ; Internal Medicine
- Record Identifier
- 9984949224302771
Metrics
1 Record Views